Latest news
Immunovant Q1 Earnings Call Highlights - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 19:04:19 GMTIMVT: Imminent brepocitinib DM launch, robust cash, and major late-stage catalysts ahead - TradingViewTradingView · Thu, 06 Aug 2026 15:05:49 GMTPriovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS) - globenewswire.comglobenewswire.com · Thu, 06 Aug 2026 11:00:00 GMT